Dechert is serving as special transaction counsel to Aquestive Therapeutics, Inc. in its royalty monetization agreement with Marathon Asset Management, a leading global investment firm, that will result in proceeds to the Company of up to $125 million. In exchange for this funding, Marathon will be entitled to receive all royalties and other payments due under Aquestive’s license agreement with Sunovion Pharmaceuticals Inc. as a result of Sunovion’s commercialization of KYNMOBI™ (apomorphine HCI) sublingual film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.
Under the terms of the agreement, Aquestive will receive $40 million at closing and is eligible to receive up to $85 million of contingent payments at various points, beginning as early as the fourth quarter of 2020, based on the achievement of certain worldwide royalty targets and certain other commercial milestones. The transaction is anticipated to close later this month.
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.
The Dechert team advising Aquestive Therapeutics includes corporate partner David Rosenthal and finance counsel Joshua Strathman.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
